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ABSTRACT 
The aim of treating hyperbilirubinemia is preventing the serum bilirubin to reach neurotoxic 
levels, which is done by phototherapy or blood transfusion. However, pharmacological treat-
ments still remain vague. Therefore the effects of adding either clofibrate or phenobarbital on 
treatment outcomes was evaluated in icteric non-hemolitic newborns. Ninety neonates were 
divided in three groups. Two groups were prescribed 100 mg/kg clofibrate or 5 mg/kg pheno-
barbital orally as single dose on arrival, in addition to phototherapy. The control group only 
received phototherapy. Serum bilirubin was evaluated at the reception and 12, 24, 48 and 
72 hours after beginning of drug therapy. Total bilirubin levels decreased in treated groups 
compared with the control group in all samples taken (12, 24, 48 and 72 hours). Clofibrate 
effect in decreasing bilirubin level was more prominent (14 % and 32 % after 12 and 72 h re-
spectively). In addition duration of hospitalization and length of phototherapy decreased in 
clofibrate and phenobarbital groups compared with control group (1.5, 2 days respectively, vs. 
2.6 days). Therefore using clofibrate and phenobarbital in icteric neonates are supportive not 
only by decreasing the serum bilirubin level, but also by lessening the duration of hospitaliza-
tion and phototherapy. Thus in addition to cost benefits for the patient these drugs can reduce 
the risks of transfusion, and clofibrate seems more promising in this regard.  
 
Keywords: hyperbilirubinemia, jaundice, non-hemolytic, phototherapy 
 
 
 
INTRODUCTION 
Hyperbilirubinemia is the most common 
morbidity in the neonatal period and 5-
10 % of all newborns require intervention 
for pathological jaundice. It is also the most 
common clinical problem among the new-
borns, especially in south of Asia (Maisels 
and Watchko, 2012). Hyperbilirubinemia 
can be caused by overproduction of biliru-
bin, decrease in liver absorption, conjuga-
tion impairment and increase in bilirubin 
enterohepatic cycle (Stevenson et al., 
2004). In babies whose bilirubin blood lev-
els reach risky levels, bilirubin may cross 
the blood brain and cause reversible dam-
age (called early acute bilirubin encephalo-
pathy) or permanent damage (called kernic-
terus). Although phototherapy and in case 
of very high serum bilirubin levels, blood 
transfusion has been used, but these meth-
ods prove to have side effects (Maisels and 
Newman, 2005). Evidently clofibrate and 
phenobarbital are useful for treatment of 
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hyperbilirubinemia in newborns (Dortmann 
et al., 1992; Dennery, 2002).  
Thus the reduction of serum bilirubin 
level, is an important approach in jaundice 
newborns. Clofibrate and phenobarbital are 
not in routine therapeutic regimens of these 
patients; therefore it was aimed to compare 
their effectiveness in the treatment of icteric 
newborns that received phototherapy as the 
sole therapy regimen. 
 
METHODS AND MATERIALS 
In a randomized clinical trial (registra-
tion number: IRCT201202199073N1), 90 
term newborns (48 male, 42 female) aged 
between 3-10 days, which were diagnosed 
with non-hemolytic jaundice at the hospital, 
were evaluated. The birth weight and deliv-
ery age of studied cases were 3185 gr  340 
and 38.8 weeks  0.7 respectively. Includ-
ing criteria were as follow: term neonates 
(37-42 weeks age), birth weight 2/5-4 kg, 
breast feeding, jaundice beginning at days 
3-11 after birth, and indirect bilirubin level 
between 15-20 mg/dl. Laboratory tests in-
cluding ABO and Rh, cell blood count 
(CBC), retic count, peripheral blood smear, 
G6PD enzyme assay and combs test were 
performed for all the cases. Infants with 
hemolytic hyperbilirubinemia, background 
disorders, sepsis, physical anomalies and 
impaired hematologic tests were excluded. 
Included infants were classified in three 
groups randomly. Group 1 was prescribed 
100 mg/kg oral clofibrate, as a single dose 
in the first day and distilled water on the 
two following days. Group 2 was pre-
scribed 5 mg/kg oral phenobarbital as a sin-
gle dose on the first day and distilled water 
on days 2 and 3. Finally, control group was 
prescribed distilled water for 3 days. Photo-
therapy was performed for all the groups 
(wave length 420-460 nm). Total serum bil-
irubin, direct and indirect bilirubin were 
evaluated at the reception and 12, 24, 48 
and 72 hours after therapy. Duration of 
hospitalization and length of photoherapy 
were also considered. The experiments 
were undertaken with the understanding 
and written permission from each child's 
parents. 
The data were analyzed using GraphPad 
Prism software. The data were analyzed by 
one-way analysis of variance (ANOVA), 
followed by Duncan’s multiple comparison 
tests. Results are expressed as the group 
mean ± SD, P values < 0.05 are considered 
significant. 
 
RESULTS 
The difference between age, weight and 
delivery age of studied newborns in 3 tested 
groups was not significant. In this study 
70 % of the enfants were born with normal 
delivery and 30 % by cesarean section. 
There was no significant difference regard-
ing the type of delivery between the groups. 
Serum bilirubin level of newborns in the 
study groups, on arrival was 17.5  
1.4 mg/dl, there was no important differ-
ence between the groups. However, de-
crease in the serum bilirubin level differed 
significantly between the 3 groups 12, 24, 
48 and 72 h after the beginning of therapy 
(Figure 1). That is, 12 h after therapy serum 
bilirubin level in group 1 (clofibrate) and 
group 2 (phenobarbital) decreased by 21 % 
and 16 % respectively while it decreased 
only 8.5 % in control group. Furthermore, 
the rate of bilirubin decrease in group 1 was 
sharper than group 2 (Figure 1). After 24 h 
the corresponding figure decreased 37 %, 
26.8 % and 18.5 % in group 1, 2 and con-
trol respectively. 
The duration of hospitalization in the in-
fants was 2 days  0.7. That is group 1, 
were hospitalized for 1.5 days  0.5, group 
2 for 2 days  0.6 and control group for 
2.6 days  0.6. Therefore duration of photo-
therapy was also significantly different 
among the groups. 
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Figure 1: The effect of 100 mg/kg clofibrate or 5 mg/kg phenobarbital in addition to phototherapy, and 
phototherapy alone on the level of serum bilirubin 0, 12, 24, 48, and 72 h after reception. Results are 
expressed as group mean ± SD, n=30 in each group, ***P < 0.001 and **P < 0.01 compared to control 
values, # P < 0.05 and # # P < 0.01 compared to phenobarbital values 
 
 
 
Group 1 underwent 1/5 days  0.5 of 
phototherapy, while group 2 and controls 
went through 2 days  0.6 and 2.6 days  
0.6 of phototherapy, respectively. Accord-
ing to our results, no side effects were 
observed by clofibrate and phenobarbital 
single dose in this study.  
 
DISCUSSION 
Based on our findings, clofibrate effect 
on decreasing the serum bilirubin level was 
further than phenobarbital. Adding these 
drugs to phototherapy had a much higher 
effect in reducing the serum bilirubin level 
than using phototherapy alone 12, 24, 48, 
72 h after reception. Besides, clofibrate 
reduced the duration of phototherapy and 
hospitalization that is of great importance. 
Prescribing a single dose of these two drugs 
had no side effects in newborns, which is in 
accordance with previous reports (Linden-
baum et al., 1981; Suh et al., 1996).  
The management and detection of 
neonatal jaundice in healthy term and near 
term infants continue to remain a challenge 
partly because jaundice is common. 
Although kernikterus is rare but it is very 
important because of its consequences. 
Therefore finding approaches for better 
management of hyperbilirubinemia is 
critical. While phototherapy is an effective 
intervention that decreases bilirubin con-
centration (Sankaran, 2010). Due to its 
complications it would be vital trying to 
reduce the duration of phototherapy. 
It has been reported that clofibrate 
decreases the bilirubin level of icteric 
newborns (Lindenbaum et al., 1981). 
Similarly, the duration of hospitalization 
and phototherapy was decreased. In study 
of Suh and co-workers (1996), pheno-
barbital was prescribed for jaundice 
newborns or to their pregnant mothers three 
days before delivery. Their results showed 
that serum bilirubin level in newborns 
taking phenobarbital was significantly 
lower than those whom the drug was 
prescribed for their mothers and also 
control group. Phenobarbital also proved 
efficacy on decreasing serum bilirubin level 
in our study. It should be mentioned that, in 
the previous study 3 mg/kg phenobarbital 
was used as intramuscular injection, in the 
present study 5 mg/kg phenobarbital was 
used orally. Further investigations may be 
necessary to evaluate the best route of drug 
prescription in icteric newborns.  
In another study in Mexico (Bonifacio 
et al., 2001), similar evaluation on icteric 
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newborns was performed using two drugs 
phenobarbital and clofibrate together. Their 
results showed that there were no 
significant differences between the effects 
of these two drugs in decreasing the serum 
bilirubin level in infants. This is in contrast 
with our results that clofibrate was more 
effective than phenobarbital in treatment of 
newborns with hyperbilirubinemia.  
Some studies have focused on the dose 
of drugs used in treatment of hyperbili-
rubinemia. Zahedpasha and co-workers 
(2007) showed that there is no significant 
difference between 25 and 50 mg/kg of 
clofibrate in decreasing the serum bilirubin 
level in icteric newborns.  
In general, according to the results of 
our study, we concluded that, clofibrate and 
phenobarbital are effective for treatment of 
hyperbilirubinemia in icteric newborns and 
clofibrate is more suitable. Therefore 
clofibrate could be used as a safe drug in 
addition to phototherapy for treatment of 
newborns with non-hemolytic hyperbili-
rubinemia, due to its appropriate effective-
ness and possibility of single dose pre-
scription. It also reduces the length of 
hospitalization that would be of importance 
regarding financial matters as well.  
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